SCHEMBL6498907

SCHEMBL6498907

O=C(O)c1cc(Cl)ccc1-c1ccc(Cl)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.61
TP53 P04637 1/20 0.61
HSD17B10 Q99714 3/20 0.60
CA1 P00915 1/20 0.59
CA2 P00918 1/20 0.59
SMN1; SMN2 Q16637 2/20 0.55
TSHR P16473 1/20 0.55
CASP1 P29466 1/20 0.55
SRD5A2 P31213 1/20 0.54
EIF4E P06730 3/20 0.54
PTGES O14684 1/20 0.51
ALOX5 P09917 1/20 0.51
CYP2C9 P11712 1/20 0.51
HPGD P15428 1/20 0.51
CASP7 P55210 1/20 0.51
HIF1A Q16665 1/20 0.51
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
MARS1 P56192 1/20 0.50
AURKA O14965 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4280740 0.90 FOLH1 (0.59) ALDH1A1TP53HSD17B10CA1CA2
SCHEMBL6495629 0.89 DHODH (0.60) ALDH1A1TP53HSD17B10CA1CA2
SCHEMBL6490357 0.89 DHODH (0.60) ALDH1A1TP53HSD17B10CA1CA2
SCHEMBL3814907 0.89 HSD17B10 (0.79) ALDH1A1TP53HSD17B10CA1CA2
SCHEMBL6488777 0.87 ANO1 (0.52) ALDH1A1TP53HSD17B10CA1CA2
SCHEMBL6499129 0.87 HSD17B10 (0.51) ALDH1A1TP53HSD17B10CA1CA2
SCHEMBL19514758 0.87 ALDH1A1 (0.71) ALDH1A1TP53HSD17B10CA1CA2
SCHEMBL809394 0.86 ALDH1A1 (0.59) ALDH1A1TP53HSD17B10CA1CA2
SCHEMBL6492505 0.84 CYP2C8 (0.57) ALDH1A1TP53HSD17B10CA1CA2
SCHEMBL3818624 0.83 EIF4E (0.52) ALDH1A1TP53HSD17B10CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 ALDH1A1 1603/4885TP53 3031/4885HSD17B10 901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.